CN104356125A - Triazole alcohol antifungal compound with side chain containing piperidine oxadiazole as well as preparation method and application thereof - Google Patents
Triazole alcohol antifungal compound with side chain containing piperidine oxadiazole as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN104356125A CN104356125A CN201410582367.9A CN201410582367A CN104356125A CN 104356125 A CN104356125 A CN 104356125A CN 201410582367 A CN201410582367 A CN 201410582367A CN 104356125 A CN104356125 A CN 104356125A
- Authority
- CN
- China
- Prior art keywords
- group
- oxadiazoles
- piperidyl
- piperidines
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of medicine, and provides a class of 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-((piperidine oxadiazole side chain substituted))-2-propanol compound, which comprises cis-trans-isomers of the compound and any mixture of these forms or medical salts thereof. The chemical structure of the compound is as shown in a formula (I) in the Specification. The invention further provides a preparation method of the compound, and an application in the preparation of an antifungal drug. Antifungal experiments show that the compound has excellent antifungal effect for various shallow and deep funguses; compared with an existing antifungal drug such as fluconazole in clinical application, the compound has the advantages of high efficiency, low toxicity and wide antifungal spectrum, and can be used for preparing new antifungal drugs.
Description
Technical field
The present invention relates to medical art, be specifically related to a class and there is trinitrogenazole alcohol antifungal compound and preparation method thereof containing piperidines oxadiazoles side chain and application and preparation method thereof, and the application in medicine.
Background technology
In recent years, along with the extensive application of broad-spectrum antibiotics, antitumour drug, immunosuppressor, extensively carrying out of radiotherapy and organ transplantation, generally carrying out of conduit and intubate, and the increase rapidly of immune deficient patients especially AIDS patient, cause fungi infestation particularly deep fungal infection significantly rise, deep fungal infection has now become the major disease such as acquired immune deficiency syndrome (AIDS) and tumour main causes of death.Existing antifungal drug mainly contains the amphotericin B acting on fungal cell's membrane lipid, the nitrogen azole drug (fluconazole, the itraconazole that act on lanosterol 14-demethylase.Voriconazole etc.) and act on the fat peptide medicament (Caspofungin, MFG and anidulafungin etc.) of cell walls-(1,3)-glucan synthase.But with regard to its clinical application, there is the problems such as side effect is large, narrow antimicrobial spectrum, easily generation resistance in existing antifungal drug, far can not meet clinical treatment needs.Exploitation wide spectrum, novel antifungal drugs that is efficient and low toxicity are significant.
The seminar at the present inventor place has carried out going deep into systematic research to triazole antifungal compound, and synthesized a collection of highly active triazole antifungal compound, the Chinese patent applied for is as follows:
CN200510026331.3, substituted triazolone benzyl amine triazole antifungal compounds and preparation method thereof, publication number is CN1699351A;
CN02136947.X, novel diazo alcoholic antifungal compound and its esters, publication number is CN1405157A;
CN200810202725.3, substituted phenoxy oxygen alkylamine triazole alcohol antimycotic compounds and preparation method thereof, publication number is CN101402613A;
CN200910200074.9, piperidine-4-ketone-O-substituted oxime triadimenol-type antifungal compound and preparation method thereof, publication number is CN101723933A;
CN201010117525.5, triazole alcoholic antifungal compound that n-formyl sarcolysine base side chain replaces and preparation method thereof, publication number is CN101781263A
The present inventor is devoted to carry out structural modification on this basis always, strengthens the activity of compound, improves bioavailability, reduces toxicity, therefrom find new triazole antifungal compound.
Summary of the invention
The object of the invention is to develop the trinitrogenazole alcohol antifungal medicine that wide spectrum, a class that is efficient and low toxicity are novel, specifically 1-(1H-1,2,4-triazol-1-yl)-2-(2,4-difluorophenyl)-3-(piperidines oxadiazoles side substitution)-2-propanol compound and pharmaceutical salts thereof, another object of the present invention is to the preparation method that this compounds is provided, and prepare the application in antifungal drug.
The present inventor passes through the homology mould technique construction three-dimensional structure of lanosterol 14α-demethylase of fungi (Sheng Chunquan, Zhang Wannian, Homology modeling of lanosterol 14 α-demethylase of Candida albicans and Aspergillus fumigatus and insights into the enzyme-substrate interactions, J Biomol Struct Dyn, 22 (1): 91-99), and carry out the reasonably optimizing design studies of azole drug on this basis, design and synthesize the trinitrogenazole alcohol antifungal compound with novel nitrogen-containing side chain.
A first aspect of the present invention, provide a kind of novel diazo alcoholic antifungal compound of efficient, low toxicity, wide spectrum, be specially 1-(1H-1,2,4-triazol-1-yl)-2-(2,4-difluorophenyl)-3-((piperidines oxadiazoles side substitution))-2-propanol compound, comprise any mixture or its pharmaceutical salts of its cis-trans-isomer and its these forms, the chemical structure of described compound is as shown in formula I:
In formula:
X group represents piperidyl;
Y group represents 1,2,4-oxadiazoles and 1,3,4-oxadiazoles;
R group represents substituted benzene or heterocyclic substituent, the substituent position of substituted benzene can be positioned at neighbour, contraposition, also can be polysubstituted; The substituted radical of substituted benzene comprises:
(a) halogen: F, Cl;
(b) aliphatic chain, as methyl, ethyl, trifluoromethyl, methoxyl group etc., particularly preferably 4-methoxy substitution;
(c) nitro;
Wherein the position of substitution of heterocyclic substituent can be positioned at other carbon atom except heteroatoms; Heterocyclic substituent refers to: thienyl, furyl, pyridyl, xenyl.
Present invention also offers the pharmacy acceptable salt of above-claimed cpd, its pharmacy acceptable salt includes but not limited to: hydrochloride, vitriol, nitrate, hydrosulfate, hydrobromate, acetate, oxalate, Citrate trianion, mesylate or methane sulfonates etc.
It can be its raceme that above-mentioned aromatic ring replaces oxadiazoles piperidines Novel Triazole Alcohols, also can be its R type or S type isomer.
In formula I, the present invention is through the good compound of test anti-mycotic efficiency, and the combination of described X, Y and R group is as follows respectively:
(1) L group is piperidyl, and Y group is 1,3,4-oxadiazoles, and R group is 3-pyridyl.
(2) L group is piperidyl, and Y group is 1,3,4-oxadiazoles, and R group is 4-pyridyl.
(3) L group is piperidyl, and Y group is 1,3,4-oxadiazoles, and R group is 2-furyl.
(4) L group is piperidyl, and Y group is 1,3,4-oxadiazoles, and R group is phenyl.
(5) L group is piperidyl, and Y group is 1,3,4-oxadiazoles, and R group is 2-fluorophenyl.
(6) L group is piperidyl, and Y group is 1,3,4-oxadiazoles, and R group is 4-fluorophenyl.
(7) L group is piperidyl, and Y group is 1,3,4-oxadiazoles, and R group is 2,6-difluorophenyl.
(8) L group is piperidyl, and Y group is 1,3,4-oxadiazoles, and R group is 4-chloro-phenyl-.
(9) L group is piperidyl, and Y group is 1,3,4-oxadiazoles, and R group is 2-aminomethyl phenyl.
(10) L group is piperidyl, and Y group is 1,3,4-oxadiazoles, and R group is 3-aminomethyl phenyl.
(11) L group is piperidyl, and Y group is 1,3,4-oxadiazoles, and R group is 4-ethylphenyl.
(12) L group is piperidyl, and Y group is 1,3,4-oxadiazoles, and R group is 4-p-methoxy-phenyl.
(13) L group is piperidyl, and Y group is 1,3,4-oxadiazoles, and R group is 4-trifluoromethyl.
(14) L group is piperidyl, and Y group is 1,3,4-oxadiazoles, and R group is 4-nitrophenyl.
(15) L group is piperidyl, and Y group is 1,3,4-oxadiazoles, and R group is 1-naphthyl.
(16) L group is piperidyl, and Y group is 1,2,4-oxadiazoles, and R group is 3-pyridyl.
(17) L group is piperidyl, and Y group is 1,2,4-oxadiazoles, and R group is 3-p-methoxy-phenyl.
(18) L group is piperidyl, and Y group is 1,2,4-oxadiazoles, and R group is 4-p-methoxy-phenyl.
(19) L group is piperidyl, and Y group is 1,2,4-oxadiazoles, and R group is 2-furyl.
(20) L group is piperidyl, and Y group is 1,2,4-oxadiazoles, and R group is 2-thienyl.
(21) L group is piperidyl, and Y group is 1,2,4-oxadiazoles, and R group is 3-thienyl.
(22) L group is piperidyl, and Y group is 1,2,4-oxadiazoles, and R group is 4-trifluoromethyl.
(23) L group is piperidyl, and Y group is 1,2,4-oxadiazoles, and R group is 4-aminomethyl phenyl.
(24) L group is piperidyl, and Y group is 1,2,4-oxadiazoles, and R group is 4-fluorophenyl.
(25) L group is piperidyl, and Y group is 1,2,4-oxadiazoles, and R group is the fluoro-4-trifluoromethyl of 2-.
The chemical structure of above-mentioned preferred compound, productive rate, molecular formula are as shown in table 1, and spectroscopic data is in table 2, and the compound corresponding to the compound number in the present invention in table 1, table 2, table 3 is consistent.
The chemical structure of table 1 part preferred compound, productive rate and molecular formula
The nuclear magnetic data of table 2 part preferred compound
A second aspect of the present invention, provide above-mentioned 1-(1H-1,2,4-triazol-1-yl)-2-(2,4-difluorophenyl)-3-((piperidines oxadiazoles side substitution))-2-propanol compound, comprise any mixture of its cis-trans-isomer and its these forms or the preparation method of its pharmaceutical salts, the building-up reactions flow process of its compound is as follows:
The first step
Second step: (A) piperidinyl-1,3,4-furodiazole substituting group synthetic route:
Second step: (B) piperidinyl-1,2,4-furodiazole substituting group synthetic route:
The synthesis of the compounds of this invention salt is on the basis of above-mentioned reaction, does following reaction further:
Wherein HX represents hydrochloric acid, sulfuric acid, nitric acid, Hydrogen bromide, acetic acid, oxalic acid, citric acid or methanesulfonic etc.
The preparation method of the compounds of this invention, concrete steps are:
The first step: preparation 1-[2-(2,4 difluorobenzene base)-2,3-epoxypropyl]-1H-1,2,4-triazolium methanesulfonat (II)
2-(1H-1,2,4-triazol-1-yl)-2', 4'-difluoro acetophenone and iodate trimethylammonium oxygen sulphur, trimethylammonium hexadecyl brometo de amonio, in toluene and sodium hydroxide, reaction generates 1-[2-(2,4 difluorobenzene base)-2,3-epoxypropyl]-1H-1,2,4-triazolium methanesulfonat (II);
Second step: be selected from (A) piperidinyl-1,3,4-furodiazole replaces or (B) piperidinyl-1, and 2,4-furodiazole replaces
(A) piperidinyl-1,3,4-furodiazole replaces:
(A1) N-Boc-hydrazine carbonyl piperidines (III) is prepared
Containing the ethanolic soln of N-Boc-piperidine methyl formate and hydrazine hydrate, stir in ethanol and spend the night, generate N-Boc-hydrazine carbonyl piperidines (III);
(A2) N-Boc-hydrazides carbonyl piperidines (IV) is prepared
The formyl chloride of N-Boc-hydrazine carbonyl piperidines (III) side chain and various aromatic base, in methylene dichloride, adds triethylamine, generates N-Boc-hydrazides carbonyl piperidines (IV);
(A3) N-Boc-4-(1,3,4-oxadiazoles-2-base) piperidines (V) is prepared
N-Boc-hydrazides carbonyl piperidines (IV), in tetrahydrofuran solution, adds p-methyl benzene sulfonic chloride and triethylamine, back flow reaction, generates N-Boc-4-(1,3,4-oxadiazoles-2-base) piperidines (V);
(A4) 4-(1,3,4-oxadiazoles-2-base) piperidine sidechains (VI) is prepared
Different N-Boc-4-(1,3,4-oxadiazoles-2-base) piperidineses (V) is in dichloromethane solution, add trifluoroacetic acid, stirring is spent the night, and generates 4-(1,3,4-oxadiazoles-2-base) piperidine sidechains (VI);
(A5) target compound (VII) is prepared
Different 4-(1,3,4-oxadiazoles-2-base) piperidine sidechains (VI) and 1-[2-(2,4-difluorophenyl)-2,3-epoxypropyl]-1H-1,2,4-triazolium methanesulfonat (II) in ethanol, take triethylamine as alkali, 80 DEG C of back flow reaction 6 ~ 9h, generate target compound (VII);
(B) piperidinyl-1,2,4-furodiazole replaces:
(B1) aromatic ring substituted hydroxy amidine (VIII) is prepared
Various nitrile and oxammonium hydrochloride in ethanol, with NaHCO
3for alkali, 80 DEG C of back flow reaction 8h, generate the cyclosubstituted hydroxyamidines of various virtue (VIII);
(B2) N-Boc-4-(1,2,4-oxadiazoles-5-base) piperidines (IX) is prepared
Various aromatic ring substituted hydroxy amidine (VIII) and N-Boc-piperidine carboxylic acid are in dioxane, at HOBt, under the catalysis of EDCI, take DIPEA as alkali, 85 DEG C of back flow reaction 7h-10h, generate N-Boc-4-(1,2,4-oxadiazoles-5-base) piperidines (IX);
(B3) 4-(1,2,4-oxadiazoles-5-base) piperidines side chain (X) is prepared
N-Boc-4-(1,2,4-oxadiazoles-5-base) piperidines side chain (IX) is dissolved in methylene dichloride, adds trifluoroacetic acid, generates 4-(1,2,4-oxadiazoles-5-base) piperidines side chain (X);
(B4) target compound (XI) is prepared
Different 4-(1,2,4-oxadiazoles-5-base) piperidines side chain (X) and 1-[2-(2,4-difluorophenyl)-2,3-epoxypropyl]-1H-1,2,4-triazolium methanesulfonat (II) in ethanol, take triethylamine as alkali, 80 DEG C of back flow reaction 6 ~ 9h, generate target compound (XI);
The present invention also comprises, the synthesis of the compounds of this invention pharmacy acceptable salt:
Target compound (XI) and excessive acid at room temperature react 2 ~ 3 hours, and generate target compound (M), acid is hydrochloric acid, sulfuric acid, nitric acid, Hydrogen bromide, acetic acid, oxalic acid, citric acid or methanesulfonic.
A third aspect of the present invention, provide above-mentioned 1-(1H-1,2,4-triazol-1-yl)-2-(2,4-difluorophenyl)-3-((piperidines oxadiazoles side substitution))-2-propanol compound, comprise any mixture or its pharmaceutical salts of its cis-trans-isomer and its these forms, prepare the application in antifungal drug.
The compounds of this invention finds through antimycotic experiment, to various superficial part and deep fungal, there is very strong anti-mycotic efficiency, as Candida albicans, Candida parapsilosis, Cryptococcus neoformans, Candida glabrata, aspergillus fumigatus, trichophyton, gypsum shape sporidiole bacteria etc.
The antifungal drug of the present invention and existing clinical application, as compared with fluconazole, has advantage that is efficient, low, the antimycotic spectrum width of toxicity, can be used for preparing new antifungal drug.
Embodiment
Now in conjunction with the embodiments, the invention will be further described, but enforcement of the present invention is not limited in this.
The preparation of embodiment 1:1-[2-(2,4 difluorobenzene base)-2,3-epoxypropyl]-1H-1,2,4-triazolium methanesulfonat (II)
Get 2-(1H-1, 2, 4-triazol-1-yl)-2', 4'-difluoro acetophenone (I) 29.8g (0.115mol), trimethylammonium oxygen sulfuration iodine 25.3g (0.115mol), trimethylammonium hexadecyl brometo de amonio 1.6g, put into 500ml three-necked bottle, add toluene 180ml and 20% sodium hydroxide solution (w/w) 225ml, 60 DEG C are heated 3 hours, after reaction terminates, isolate toluene layer, aqueous layer with ethyl acetate extraction (100mlX2), merge organic layer, be washed to neutrality, solvent evaporated, debris adds 120ml diluted ethyl acetate, the ethyl acetate 2ml being dissolved with 8.3g methylsulfonic acid is dripped at 0 DEG C, separate out faint yellow solid, filter, by recrystallizing methanol, obtain compounds Ⅳ 21.71g, productive rate 56.7%, fusing point: 128 ~ 129 DEG C.
The preparation of embodiment 2:N-Boc-4-hydrazine carbonyl piperidines (III)
N-tertbutyloxycarbonyl-4-piperidine carboxylic acid methyl esters 2g (7.77mmol) is dissolved in (1:1) mixed solvent (30mL) of hydrazine hydrate and ethanol, and under room temperature, stirring is spent the night.Ethanol is concentrated into dry, adds in water (50mL), and with methylene dichloride (50mL × 3), anhydrous sodium sulfate drying, filters, concentrated, obtains white solid 1.8g, yield 95%.
The preparation of embodiment 3:N-Boc-4-hydrazides carbonyl piperidines (IV compounds)
Get N-Boc-4-hydrazine carbonyl piperidines 0.2g (0.82mmol), triethylamine 0.12g (1.23mmol) is dissolved in methylene dichloride (20mL), nicotinoyl chlorine 0.22g (1.23mmol) is slowly added, stirring at room temperature 2 hours under ice bath.Add methylene dichloride (30mL) dilution, with saturated aqueous common salt (20mL × 3) washing, anhydrous sodium sulfate drying, filter, concentrated, gained crude product silica gel column chromatography (ethyl acetate: methyl alcohol=50:1-30:1), obtain white solid 0.2g, yield 70%.
Other IV compounds for raw material, are that raw material react from different aryl formyl chlorides with III, and the step repeated in embodiment 3 obtains.
The preparation of embodiment 4:N-Boc-4-(1,3,4-oxadiazoles-2-base) piperidines (V compounds)
N-Boc-4-nicotinic acid hydrazide carbonyl piperidines 0.18 (0.52mmol), triethylamine 0.3g (3.12mmol) is dissolved in dry tetrahydrofuran solution (10mL), add p-methyl benzene sulfonic chloride 0.3g (1.56mmol), 60 DEG C of backflow 10h.The direct silica gel column chromatography of gained crude product (ethyl acetate: methyl alcohol=80:1-50:1), obtain faint yellow solid 0.12g, yield 71%, obtains N-Boc-4-[5-(3-pyridyl)-1,3,4-(2-oxadiazoles base)] piperidines.
Other V compounds, react with Tosyl chloride for raw material with different IV, and the step repeated in embodiment 4 obtains.
The preparation of embodiment 5:4-(1,3,4-oxadiazoles-2-base) piperidines (VI compounds)
N-Boc-4-[5-(3-pyridyl)-1,3,4-(2-oxadiazoles base)] piperidines 0.24g (0.72mmol) is dissolved in 20mL methylene dichloride, adds trifluoroacetic acid 3mL stirring and spends the night.Wet chemical (3g) slowly adds neutralization reaction liquid, adds dichloromethane extraction water layer, combined dichloromethane, dry, obtains brown solid 149mg, yield 92%.
Other VI compounds are with different V for raw material, and add trifluoroacetic acid, stirring is spent the night, and repeat step in embodiment 5 and obtain.
Embodiment 6:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[5-(3-pyridine-1-base)-1,3,4-oxadiazoles-2-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 1)
4-[5-(3-pyridyl)-1,3,4-(2-oxadiazoles base)] piperidines 0.14g (0.61mmol) is dissolved in 10mL ethanol, add 1-[2-(2,4 difluorobenzene base)-2,3-epoxypropyl]-1H-1,2,4-triazolium methanesulfonat (II) 0.20g, triethylamine 1mL, 75 DEG C of backflow 12h.The direct silica gel column chromatography of gained crude product (methylene dichloride: methyl alcohol=100:1-100:5), obtains yellow solid 0.15g, yield 73%.
Embodiment 7:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[5-(4-pyridine-1-base)-1,3,4-oxadiazoles-2-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 2)
Get different nicotinoyl chlorine and III to react in methylene dichloride, preparation method is with reference to embodiment 3, and later step, with reference to embodiment 4,5,6, obtains target product.
Embodiment 8:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[5-(2-furans-1-base)-1,3,4-oxadiazoles-2-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 3)
Get furoyl chloride and III to react in methylene dichloride, preparation method is with reference to embodiment 3, and later step, with reference to embodiment 4,5,6, obtains target product.
The preparation of embodiment 9:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-[4-(5-phenyl-1,3,4-oxadiazoles-2-base) piperidin-1-yl]-2-propyl alcohol (compound 4)
Get Benzoyl chloride and III to react in methylene dichloride, preparation method is with reference to embodiment 3, and later step, with reference to embodiment 4,5,6, obtains target product.
Embodiment 10:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[5-(2-fluorophenyl)-1,3,4-oxadiazoles-2-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 5)
Get o-fluoro-benzoyl chloride and III to react in methylene dichloride, preparation method is with reference to embodiment 3, and later step, with reference to embodiment 4,5,6, obtains target product.
Embodiment 11:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[5-(4-fluorophenyl)-1,3,4-oxadiazoles-2-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 6)
Get and react in methylene dichloride fluorobenzoyl chloride and III, preparation method is with reference to embodiment 3, and later step, with reference to embodiment 4,5,6, obtains target product.
Embodiment 12:1-(1H-1,2,4-triazol-1-yl)-2-(2,4-difluorophenyl)-3-{4-[5-(2,6-difluorophenyl)-1,3,4-oxadiazoles-2-bases] piperidin-1-yl } preparation of-2-propyl alcohol (compound 7)
Get 2,6-difluoro benzoyl chloride and III to react in methylene dichloride, preparation method is with reference to embodiment 3, and later step, with reference to embodiment 4,5,6, obtains target product.
Embodiment 13:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[5-(4-chloro-phenyl-)-1,3,4-oxadiazoles-2-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 8)
Get parachlorobenzoyl chloride and III to react in methylene dichloride, preparation method is with reference to embodiment 3, and later step, with reference to embodiment 4,5,6, obtains target product.
Embodiment 14:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[5-(2-aminomethyl phenyl)-1,3,4-oxadiazoles-2-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 9).
Get o-methyl-benzene formyl chloride and III to react in methylene dichloride, preparation method is with reference to embodiment 3, and later step, with reference to embodiment 4,5,6, obtains target product.
Embodiment 15:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[5-(3-aminomethyl phenyl)-1,3,4-oxadiazoles-2-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 10).
Get m-methyl benzoyl formyl chloride and III to react in methylene dichloride, preparation method is with reference to embodiment 3, and later step, with reference to embodiment 4,5,6, obtains target product.
Embodiment 16:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[5-(4-ethylphenyl)-1,3,4-oxadiazoles-2-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 11).
Get p-ethylbenzoyl chloride and III to react in methylene dichloride, preparation method is with reference to embodiment 3, and later step, with reference to embodiment 4,5,6, obtains target product.
Embodiment 17:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[5-(4-p-methoxy-phenyl)-1,3,4-oxadiazoles-2-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 12).
Get anisoyl chloride and III to react in methylene dichloride, preparation method is with reference to embodiment 3, and later step, with reference to embodiment 4,5,6, obtains target product.
Embodiment 18:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[5-(4-trifluoromethyl)-1,3,4-oxadiazoles-2-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 13).
Get 4-trifluoromethyl benzoyl chloride and III to react in methylene dichloride, preparation method is with reference to embodiment 3, and later step, with reference to embodiment 4,5,6, obtains target product.
Embodiment 19:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[5-(4-nitrophenyl)-1,3,4-oxadiazoles-2-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 14).
Get 4-nitrobenzoyl chloride and III to react in methylene dichloride, preparation method is with reference to embodiment 3, and later step, with reference to embodiment 4,5,6, obtains target product.
Embodiment 20:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[5-(1-naphthyl)-1,3,4-oxadiazoles-2-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 15).
Get 1-naphthoyl chloride and III to react in methylene dichloride, preparation method is with reference to embodiment 3, and later step, with reference to embodiment 4,5,6, obtains target product.
Embodiment 21: the preparation of aromatic ring substituted hydroxy amidine compound (VIII compounds)
By nicotinonitrile 0.67g (6.4mmol), oxammonium hydrochloride 1.1g (16.7mmol), sodium bicarbonate 1.4g (16.7mmol) is dissolved in 20mL ethanol, reflux 8h, the direct silica gel column chromatography of gained crude product (ethyl acetate: sherwood oil=8:1-1:1), obtain sterling 0.79g, yield 90%, generate (Z)-N`-hydroxyl-3-picolyl ether.
Various nitrile and oxammonium hydrochloride in ethanol, with NaHCO
3for alkali, 80 DEG C of back flow reaction 8h, generate the cyclosubstituted hydroxyamidines of various virtue (VIII);
The preparation of embodiment 22:N-Boc-4-(1,2,4-oxadiazoles-5-base) piperidines (IX compounds)
By N-Boc-4-piperidine carboxylic acid 1.33g (5.8mmol), HOBt0.94g (6.96mmol), EDCI1.67g (8.70mmol), diisopropyl ethyl amine 1.50g (11.6mmol) is dissolved in 50mL dioxane, stirring at room temperature 15 minutes, add (Z)-N`-hydroxyl-3-picolyl ether 0.79g (5.80mmol), 85 DEG C of back flow reaction 7h, be concentrated into dry, add ethyl acetate 100mL, use water (20mL × 2) successively, NaOH solution (20mL × 2), saturated aqueous common salt (20mL × 2) washs, anhydrous sodium sulfate drying, filtering and concentrating obtains the direct silica gel column chromatography of thick product (methylene dichloride: methyl alcohol=80:1-50:1), obtain white solid 0.58g, yield 31%, generate N-Boc-4-[3-(3-pyridyl)-1, 2, 4-oxadiazoles-5-base] piperidines.
Various aromatic ring substituted hydroxy amidine (VIII) and N-Boc-piperidine carboxylic acid are in dioxane, at HOBt, under the catalysis of EDCI, take DIPEA as alkali, 85 DEG C of back flow reaction 7h-10h, generate N-Boc-4-(1,2,4-oxadiazoles-5-base) piperidines (IX compounds)
The preparation of embodiment 23:4-(1,2,4-oxadiazoles-5-base) piperidines (X compounds)
X compounds for raw material, adds trifluoroacetic acid with different IX, and stirring is spent the night, and repeats step in embodiment 5 and obtains.
Embodiment 24:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[3-(3-pyridyl)-1,2,4-oxadiazoles-5-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 16)
4-[3-(3-pyridyl)-1,2,4-oxadiazoles-5-base] piperidines and 1-[2-(2,4 difluorobenzene base)-2,3-epoxypropyl]-1H-1,2,4-triazolium methanesulfonat (II) in ethanol, take triethylamine as alkali, 80 DEG C of back flow reaction 6 ~ 9h, repeat embodiment 6, obtain target product.
Embodiment 25:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[3-(3-p-methoxy-phenyl)-1,2,4-oxadiazoles-5-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 17)
Get 3-methoxy benzonitrile and oxammonium hydrochloride reacts in ethanol, preparation method is with reference to embodiment 22, and later step, with reference to embodiment 23,24,25, obtains target product.
Embodiment 26:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[3-(4-p-methoxy-phenyl)-1,2,4-oxadiazoles-5-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 18).
Get 4-methoxy benzonitrile and oxammonium hydrochloride reacts in ethanol, preparation method is with reference to embodiment 22, and later step, with reference to embodiment 23,24,25, obtains target product.
Embodiment 27:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[3-(2-furyl)-1,2,4-oxadiazoles-5-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 19).
Get 2-furans formonitrile HCN and oxammonium hydrochloride reacts in ethanol, preparation method is with reference to embodiment 22, and later step, with reference to embodiment 23,24,25, obtains target product.
Embodiment 28:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[3-(2-thienyl)-1,2,4-oxadiazoles-5-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 20).
Get 2-thiophene formonitrile HCN and oxammonium hydrochloride reacts in ethanol, preparation method is with reference to embodiment 22, and later step, with reference to embodiment 23,24,25, obtains target product.
Embodiment 29:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[3-(3-thienyl)-1,2,4-oxadiazoles-5-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 21).
Get 3-thiophene formonitrile HCN and oxammonium hydrochloride reacts in ethanol, preparation method is with reference to embodiment 22, and later step, with reference to embodiment 23,24,25, obtains target product.
Embodiment 30:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[3-(4-trifluoromethyl)-1,2,4-oxadiazoles-5-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 22).
Get 4-trifluoromethylbenzonitrile and oxammonium hydrochloride reacts in ethanol, preparation method is with reference to embodiment 22, and later step, with reference to embodiment 23,24,25, obtains target product.
Embodiment 31:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[3-(4-aminomethyl phenyl)-1,2,4-oxadiazoles-5-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 23).
Get 4-methyl benzonitrile and oxammonium hydrochloride reacts in ethanol, preparation method is with reference to embodiment 22, and later step, with reference to embodiment 23,24,25, obtains target product.
Embodiment 32:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[3-(4-fluorophenyl)-1,2,4-oxadiazoles-5-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 24).
Get 4-methyl benzonitrile and oxammonium hydrochloride reacts in ethanol, preparation method is with reference to embodiment 22, and later step, with reference to embodiment 23,24,25, obtains target product.
Embodiment 33:1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene base)-3-{4-[3-(the fluoro-4-trifluoromethyl of 2-)-1,2,4-oxadiazoles-5-base] piperidin-1-yl } preparation of-2-propyl alcohol (compound 25).
Get the fluoro-4-trifluoromethylbenzonitrile of 2-and oxammonium hydrochloride reacts in ethanol, preparation method is with reference to embodiment 22, and later step, with reference to embodiment 23,24,25, obtains target product.
Embodiment 34: the antimycotic experiment of the compounds of this invention
1-(1H-1,2,4-triazol-1-yl)-2-(2,4 difluorobenzene the base)-3-of the present invention's synthesis replaces-2-propanol compound and has antifungic action, and its pharmacological results is as follows:
(1) experimental technique: adopt conventional antibacterial experiment in vitro method (referring to: Antimicrob Agents Chemother 1995,39 (5): 1169)
1. materials and methods
(1) experimental strain
This experiment has selected following 7 kinds of common human body cause illness's standard fungal bacterial strains as screening object, and fungal bacterial strain provides by fungi strain storehouse, pharmaceutical college of The 2nd Army Medical College new drug research center.
1) Candida albicans (Candida albicans, strain number SC5314);
2) Candida parapsilosis (Candida parapsilosis, type strain ATCC22019);
3) Cryptococcus neoformans (Cryptococcus neoformans, type strain ATCC32609);
4) Candida glabrata (Candida glabrata, strain number 537);
5) aspergillus fumigatus (Aspergillus fumigatus, strain number 07544);
6) trichophyton (Trichophyton rubrum, strain number Cmccftla);
7) gypsum shape sporidiole bacteria (Microsporum gypseum, strain number Cmccfmza)
(2) test method
Bacteria suspension is prepared: above-mentioned fungi is cultivated 16 hours through YEPD liquid nutrient medium 35 DEG C, twice activation, with blood cell counting plate counting, with RPM1640 liquid nutrient medium adjustment bacteria concentration to 1X10
4~ 1X10
5individual/ml.
Drug solution preparing: get testing compound of the present invention and be dissolved in methyl-sulphoxide, is made into the medicament storage liquid of 8.0mg/ml, tests front RPM1640 and is diluted to 640 μ g/ml.
Inoculation: 96 No. 1, orifice plate holes add RPM1640100 μ l and make blank, 3-12 hole respectively adds bacteria suspension 120 μ l, No. 2 holes add bacteria suspension 160 μ l and liquid 1.6 μ l, the drug level in 2-11 hole makes 10 grade of 4 doubling dilution, and each hole drug level is respectively 64,16,4,1,0.25,0.0625,0.0156,0.0039,0.00097,0.00024 μ g/mL.No. 12 holes do not add liquid, make positive control.Drug control is fluconazole.
Cultivate and detect: set Positive control wells optical density value (OD value) as 100%, with optical density value than Positive control wells lower than 80% lowest concentration of drug for minimal inhibitory concentration value (MIC).
(2) experimental result
Antibacterial experiment in vitro result is as shown in table 3.
Table 3 part preferred compound In Vitro Anti fungi minimal inhibitory concentration value (MIC
80, μ g/ml)
FLZ:Fluconazole fluconazole in table
Experimental result shows: compound of the present invention and its esters have good anti-mycotic activity, the extracorporeal antifungal activity of overwhelming majority compound as compound is better than fluconazole, illustrates that these compounds and its esters can be used for preparing the medicine for the treatment of anti-fungal infection.
More than show and describe ultimate principle of the present invention, principal character and advantage of the present invention.The technician of the industry should understand; the present invention is not restricted to the described embodiments; what describe in above-described embodiment and specification sheets just illustrates principle of the present invention; the present invention also has various changes and modifications without departing from the spirit and scope of the present invention, and these changes and improvements all fall in the claimed scope of the invention.Application claims protection domain is defined by appending claims and equivalent thereof.
Claims (6)
1. a class 1-(1H-1,2,4-triazol-1-yl)-2-(2,4-difluorophenyl)-3-((piperidines oxadiazoles side substitution))-2-propanol compound, comprise any mixture or its pharmaceutical salts of its cis-trans-isomer and its these forms, it is characterized in that, the chemical structure of described compound is as shown in formula I:
In formula:
X group represents piperidyl;
Y group represents 1,2,4-oxadiazoles and 1,3,4-oxadiazoles;
R group represents substituted benzene or heterocyclic substituent, the substituent position of substituted benzene can be positioned at neighbour, contraposition, also can be polysubstituted; The substituted radical of substituted benzene comprises:
(a) halogen: F, Cl;
(b) aliphatic chain, as methyl, ethyl, trifluoromethyl, methoxyl group etc., particularly preferably 4-methoxy substitution;
(c) nitro;
Wherein the position of substitution of heterocyclic substituent can be positioned at other carbon atom except heteroatoms; Heterocyclic substituent refers to: thienyl, furyl, pyridyl, xenyl.
2. a class 1-(1H-1 according to claim 1,2,4-triazol-1-yl)-2-(2,4-difluorophenyl)-3-((piperidines oxadiazoles side substitution))-2-propanol compound, comprise any mixture or its pharmaceutical salts of its cis-trans-isomer and its these forms, it is characterized in that, in formula I, described X, Y and the combination of R group as follows:
L group is piperidyl, and Y group is 1,3,4-oxadiazoles, R group be 3-pyridyl,
L group is piperidyl, and Y group is 1,3,4-oxadiazoles, R group be 4-pyridyl,
L group is piperidyl, and Y group is 1,3,4-oxadiazoles, R group be 2-furyl,
L group is piperidyl, and Y group is 1,3,4-oxadiazoles, R group be phenyl,
L group is piperidyl, and Y group is 1,3,4-oxadiazoles, R group be 2-fluorophenyl,
L group is piperidyl, and Y group is 1,3,4-oxadiazoles, R group be 4-fluorophenyl,
L group is piperidyl, and Y group is 1,3,4-oxadiazoles, R group be 2,6-difluorophenyl,
L group is piperidyl, and Y group is 1,3,4-oxadiazoles, R group be 4-chloro-phenyl-,
L group is piperidyl, and Y group is 1,3,4-oxadiazoles, R group be 2-aminomethyl phenyl,
L group is piperidyl, and Y group is 1,3,4-oxadiazoles, R group be 3-aminomethyl phenyl,
L group is piperidyl, and Y group is 1,3,4-oxadiazoles, R group be 4-ethylphenyl,
L group is piperidyl, and Y group is 1,3,4-oxadiazoles, R group be 4-p-methoxy-phenyl,
L group is piperidyl, and Y group is 1,3,4-oxadiazoles, R group be 4-trifluoromethyl,
L group is piperidyl, and Y group is 1,3,4-oxadiazoles, R group be 4-nitrophenyl,
L group is piperidyl, and Y group is 1,3,4-oxadiazoles, R group be 1-naphthyl,
L group is piperidyl, and Y group is 1,2,4-oxadiazoles, R group be 3-pyridyl,
L group is piperidyl, and Y group is 1,2,4-oxadiazoles, R group be 3-p-methoxy-phenyl,
L group is piperidyl, and Y group is 1,2,4-oxadiazoles, R group be 4-p-methoxy-phenyl,
L group is piperidyl, and Y group is 1,2,4-oxadiazoles, R group be 2-furyl,
L group is piperidyl, and Y group is 1,2,4-oxadiazoles, R group be 2-thienyl,
L group is piperidyl, and Y group is 1,2,4-oxadiazoles, R group be 3-thienyl,
L group is piperidyl, and Y group is 1,2,4-oxadiazoles, R group be 4-trifluoromethyl,
L group is piperidyl, and Y group is 1,2,4-oxadiazoles, and R group is 4-aminomethyl phenyl, or
L group is piperidyl, and Y group is 1,2,4-oxadiazoles, and R group is 4-fluorophenyl.
L group is piperidyl, and Y group is 1,2,4-oxadiazoles, and R group is the fluoro-4-trifluoromethyl of 2-.
3. a class 1-(1H-1 according to claim 1 and 2,2,4-triazol-1-yl)-2-(2,4-difluorophenyl)-3-((piperidines oxadiazoles side substitution))-2-propanol compound, comprise any mixture or its pharmaceutical salts of its cis-trans-isomer and its these forms, it is characterized in that, described pharmaceutical salts is hydrochloride, vitriol, nitrate, hydrosulfate, hydrobromate, acetate, oxalate, Citrate trianion, mesylate, or methane sulfonates.
4. a class 1-(1H-1 as claimed in claim 1,2,4-triazol-1-yl)-2-(2,4-difluorophenyl)-3-((piperidines oxadiazoles side substitution))-2-propanol compound, comprise any mixture of its cis-trans-isomer and its these forms or the preparation method of its pharmaceutical salts, it is characterized in that, the building-up reactions flow process of described compound is as follows:
The first step:
Second step: (A) piperidinyl-1,3,4-furodiazole substituting group synthetic route:
Second step: (B) piperidinyl-1,2,4-furodiazole substituting group synthetic route:
The preparation method of the compounds of this invention, concrete steps are:
The first step: preparation 1-[2-(2,4 difluorobenzene base)-2,3-epoxypropyl]-1H-1,2,4-triazolium methanesulfonat (II)
2-(1H-1,2,4-triazol-1-yl)-2', 4'-difluoro acetophenone and iodate trimethylammonium oxygen sulphur, trimethylammonium hexadecyl brometo de amonio, in toluene and sodium hydroxide, reaction generates 1-[2-(2,4 difluorobenzene base)-2,3-epoxypropyl]-1H-1,2,4-triazolium methanesulfonat (II);
Second step: be selected from (A) piperidinyl-1,3,4-furodiazole replaces or (B) piperidinyl-1, and 2,4-furodiazole replaces (A) piperidinyl-1, and 3,4-furodiazole replaces:
(A1) N-Boc-hydrazine carbonyl piperidines (III) is prepared
Containing the ethanolic soln of N-Boc-piperidine methyl formate and hydrazine hydrate, stir in ethanol and spend the night, generate N-Boc-hydrazine carbonyl piperidines (III);
(A2) N-Boc-hydrazides carbonyl piperidines (IV) is prepared
The formyl chloride of N-Boc-hydrazine carbonyl piperidines (III) side chain and various aromatic base, in methylene dichloride, adds triethylamine, generates N-Boc-hydrazides carbonyl piperidines (IV);
(A3) N-Boc-4-(1,3,4-oxadiazoles-2-base) piperidines (V) is prepared
N-Boc-hydrazides carbonyl piperidines (IV), in tetrahydrofuran solution, adds p-methyl benzene sulfonic chloride and triethylamine, back flow reaction, generates N-Boc-4-(1,3,4-oxadiazoles-2-base) piperidines (V);
(A4) 4-(1,3,4-oxadiazoles-2-base) piperidine sidechains (VI) is prepared
Different N-Boc-4-(1,3,4-oxadiazoles-2-base) piperidineses (V) is in dichloromethane solution, add trifluoroacetic acid, stirring is spent the night, and generates 4-(1,3,4-oxadiazoles-2-base) piperidine sidechains (VI);
(A5) target compound (VII) is prepared
Different 4-(1,3,4-oxadiazoles-2-base) piperidine sidechains (VI) and 1-[2-(2,4-difluorophenyl)-2,3-epoxypropyl]-1H-1,2,4-triazolium methanesulfonat (II) in ethanol, take triethylamine as alkali, 80 DEG C of back flow reaction 6 ~ 9h, generate target compound (VII);
(B) piperidinyl-1,2,4-furodiazole replaces:
(B1) aromatic ring substituted hydroxy amidine (VIII) is prepared
Various nitrile and oxammonium hydrochloride in ethanol, with NaHCO
3for alkali, 80 DEG C of back flow reaction 8h, generate the cyclosubstituted hydroxyamidines of various virtue (VIII);
(B2) N-Boc-4-(1,2,4-oxadiazoles-5-base) piperidines (IX) is prepared
Various aromatic ring substituted hydroxy amidine (VIII) and N-Boc-piperidine carboxylic acid are in dioxane, at HOBt, under the catalysis of EDCI, take DIPEA as alkali, 85 DEG C of back flow reaction 7h-10h, generate N-Boc-4-(1,2,4-oxadiazoles-5-base) piperidines (IX);
(B3) 4-(1,2,4-oxadiazoles-5-base) piperidines side chain (X) is prepared
N-Boc-4-(1,2,4-oxadiazoles-5-base) piperidines side chain (IX) is dissolved in methylene dichloride, adds trifluoroacetic acid, generates 4-(1,2,4-oxadiazoles-5-base) piperidines side chain (X);
(B4) target compound (XI) is prepared
Different 4-(1,2,4-oxadiazoles-5-base) piperidines side chain (X) and 1-[2-(2,4-difluorophenyl)-2,3-epoxypropyl]-1H-1,2,4-triazolium methanesulfonat (II) in ethanol, take triethylamine as alkali, 80 DEG C of back flow reaction 6 ~ 9h, generate target compound (XI).
5. a class 1-(1H-1 according to claim 4,2,4-triazol-1-yl)-2-(2,4-difluorophenyl)-3-((piperidines oxadiazoles side substitution))-2-propanol compound, comprise any mixture of its cis-trans-isomer and its these forms or the preparation method of its pharmaceutical salts, it is characterized in that, the synthetic route of the pharmaceutical salts of described compound is as follows:
Concrete steps are: target compound (XI) and excessive acid at room temperature react 2 ~ 3 hours, generate target compound (M), wherein HX represents hydrochloric acid, sulfuric acid, nitric acid, Hydrogen bromide, acetic acid, oxalic acid, citric acid, or methanesulfonic.
6. a class 1-(1H-1 as claimed in claim 1,2,4-triazol-1-yl)-2-(2,4-difluorophenyl)-3-((piperidines oxadiazoles side substitution))-2-propanol compound, any mixture or its pharmaceutical salts that comprise its cis-trans-isomer and its these forms are preparing the application in antifungal drug.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410582367.9A CN104356125A (en) | 2014-10-27 | 2014-10-27 | Triazole alcohol antifungal compound with side chain containing piperidine oxadiazole as well as preparation method and application thereof |
| CN201510684119.XA CN105384734B (en) | 2014-10-27 | 2015-10-20 | Trinitrogenazole alcohol antifungal compound and the preparation method and application thereof with the side chain of oxadiazoles containing piperidines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410582367.9A CN104356125A (en) | 2014-10-27 | 2014-10-27 | Triazole alcohol antifungal compound with side chain containing piperidine oxadiazole as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104356125A true CN104356125A (en) | 2015-02-18 |
Family
ID=52523460
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410582367.9A Pending CN104356125A (en) | 2014-10-27 | 2014-10-27 | Triazole alcohol antifungal compound with side chain containing piperidine oxadiazole as well as preparation method and application thereof |
| CN201510684119.XA Active CN105384734B (en) | 2014-10-27 | 2015-10-20 | Trinitrogenazole alcohol antifungal compound and the preparation method and application thereof with the side chain of oxadiazoles containing piperidines |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510684119.XA Active CN105384734B (en) | 2014-10-27 | 2015-10-20 | Trinitrogenazole alcohol antifungal compound and the preparation method and application thereof with the side chain of oxadiazoles containing piperidines |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN104356125A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021156636A1 (en) * | 2020-02-05 | 2021-08-12 | King's College London | Triazole derivatives with antifungal activity |
| CN113999222A (en) * | 2021-11-19 | 2022-02-01 | 贵州大学 | Adamantyl oxadiazole-containing compounds and preparation method and application thereof |
| CN115772132A (en) * | 2022-08-05 | 2023-03-10 | 山东大学 | Amidine/guanidino modified fungal CYP51 inhibitor derivative, and preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004359646A (en) * | 2003-06-09 | 2004-12-24 | Ss Pharmaceut Co Ltd | New azole derivative with antimycotic activity |
-
2014
- 2014-10-27 CN CN201410582367.9A patent/CN104356125A/en active Pending
-
2015
- 2015-10-20 CN CN201510684119.XA patent/CN105384734B/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021156636A1 (en) * | 2020-02-05 | 2021-08-12 | King's College London | Triazole derivatives with antifungal activity |
| CN113999222A (en) * | 2021-11-19 | 2022-02-01 | 贵州大学 | Adamantyl oxadiazole-containing compounds and preparation method and application thereof |
| CN115772132A (en) * | 2022-08-05 | 2023-03-10 | 山东大学 | Amidine/guanidino modified fungal CYP51 inhibitor derivative, and preparation method and application thereof |
| CN115772132B (en) * | 2022-08-05 | 2024-03-15 | 山东大学 | Amidine/guanidyl modified fungal CYP51 inhibitor derivative, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105384734B (en) | 2018-07-17 |
| CN105384734A (en) | 2016-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peng et al. | Recent developments in azole compounds as antibacterial and antifungal agents | |
| Dayam et al. | Discovery of small molecule integrin αvβ3 antagonists as novel anticancer agents | |
| CN101519402B (en) | Thiochromone compound, synthetic method thereof and application thereof in preparation of antifungal drugs | |
| Merzouki et al. | Eco-friendly synthesis, characterization, in-silico ADMET and molecular docking analysis of novel carbazole derivatives as antibacterial and antifungal agents | |
| CN102311399A (en) | Triazole alcohol antifungal compounds with nitrogen-containing side chains, preparation method thereof and application thereof | |
| CN105384734A (en) | Triazole alcohol antifungal compound with piperidine oxadiazole side chain and preparation method for compound and application of compound | |
| Ding et al. | Discovery of novel quinazoline-2-aminothiazole hybrids containing a 4-piperidinylamide linker as potential fungicides against the phytopathogenic fungus Rhizoctonia solani | |
| Guzel et al. | Synthesis of benzimidazole-1, 2, 4-triazole derivatives as potential antifungal agents targeting 14α-demethylase | |
| KR20150027922A (en) | Novel antifungal pyridinylhydrazide derivatives | |
| Thomann et al. | Structure–Activity Relationships of 2‐Sufonylpyrimidines as Quorum‐Sensing Inhibitors to Tackle Biofilm Formation and eDNA Release of Pseudomonas aeruginosa | |
| AU2006332019A1 (en) | Substituted aromatic heterocyclic compounds as fungicides | |
| EP1694654B1 (en) | Substituted triazoles as sodium channel blockers | |
| CN103265538B (en) | A kind of azole antifungal compound and its preparation method and application | |
| He et al. | Discovery of highly potent triazole antifungal agents with piperidine-oxadiazole side chains | |
| EP3060549B1 (en) | Novel antifungal oxodihydropyridinecarbohydrazide derivative | |
| CN102503901B (en) | Zole antifungal compounds, and preparation method and application thereof | |
| Palin et al. | Structure–activity relationships and CoMFA of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic properties | |
| Elavarasan et al. | Synthesis, Spectral Analysis, In Vitro Microbiological Evaluation, and Molecular Docking Studies of Some Novel 1‐(1‐Aryl‐1H‐tetrazol‐5‐yl)‐2‐(piperidin‐1‐yl) ethanone Derivatives | |
| CN101323594B (en) | Benzyl chloride tertiary amine double azole antimicrobial compounds, preparation and medical use thereof | |
| Shi et al. | Design and synthesis of novel triazolo-lapatinib hybrids as inhibitors of breast cancer cells | |
| CN103951625B (en) | A kind of 1,2,3-triazoles class antifungal compound containing piperazinyl and its preparation method and application | |
| CN111533693A (en) | Cinnamic acid amide diazole derivative and application thereof in antifungal drugs | |
| US7541472B2 (en) | 3-Aryl-3-hydroxy-2-methylenepropionic acid esters as fungicides | |
| CN109485607A (en) | β-azole-phenyl ketone derivatives and application thereof | |
| AU2017293946A1 (en) | Indoline derivatives and method for using and producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150218 |